Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bumetanide oral - Neurochlore

Next Previous
Search
Drug Profile

Bumetanide oral - Neurochlore

Alternative Names: Bumetanide oral liquid - Neurochlore; S 95008

Latest Information Update: 08 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurochlore
  • Developer ADIR; Neurochlore; Servier
  • Class Antihypertensives; Antiparkinsonians; Behavioural disorder therapies; Benzoic acids; Heart failure therapies; Sulfonamides
  • Mechanism of Action Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pervasive child development disorders

Most Recent Events

  • 07 Sep 2021 Servier and Neurochlore terminates phase III trial in Pervasive child development disorders in Brazil, Czech Republic, Slovakia, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain and the United Kingdom, due to low efficacy (NCT03715166)
  • 07 Sep 2021 Servier and Neurochlore terminates phase III trial in Pervasive child development disorders in USA, Australia, Czech Republic, Slovakia, Brazil, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain and the United Kingdom due to low efficacy (NCT03715153)
  • 04 Oct 2018 Phase-III clinical trials in Pervasive child development disorders (In children) in Australia, USA (PO) (NCT03715153)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top